Today in Pharma, procurement and sourcing leaders need to be whole-brained. Left-side and right-side skills and talents have become equally important in these outsourcing activities. Are we pointing to the two sides of human intellect as perfected in procurement? Well, yes, and here’s the explanation from Pharma’s sourcing leaders themselves.
Bristol-Myers Squibb focuses on reduction in total cost of ownership (TCO) while capturing value-based savings (VBS) in its supplier relationship management (SRM) strategy. A bit to unpack there. We get help from Keith Robinson, Associate Director at BMS, and an originator of the BMS Global Supplier Performance and Development Initiative.
This is not a piece on retirement. It is, though, borne of the potential for supreme satisfaction when that milestone is attained. The “post years” will have much to do with financial means, but that feeling of satisfaction will also result from your “freedom to operate” during your decades of employment, and how you put that freedom to use.
Jim Miller, President, PharmSource Information Services, Inc., sounds as much like a travel agent as a pharma outsourcing prognosticator at his DCAT Week ’17 market overview on pharmaceutical contract development and manufacturing: Pharma’s billions for biologics are staying home; small molecules continue to hit the road.
Pharma and Bio in fact know exactly what they want from their contract development and manufacturing organizations: They want it all. In errant thought at the CMO Leadership Awards leads to the conclusion CMOs can’t be good at a few outsourcing services.
You never thought you’d see a headline like that in Outsourced Pharma. But I’ve rarely heard so clearly articulated the need for a deep rationalization for outsourcing. So while this is unusual for us, the industry won’t continue its amazing progress unless clearly understanding the points against as well as our points in support.
“What would happen if you lined up what I'm concerned about, with the concerns of the CMOs?” asks Bob Sheroff, Senior Vice President, Technical Operations at Agios. Well, we are about to do just that at Outsourced Pharma Boston, where Sheroff will discuss: reliability of supply, continuous compliance, and responsiveness.
Thank high-fructose sugar for pulling at least one of the brightest of a new generation into the study of chemistry, potentially the business of pharmaceuticals, and maybe even the field of outsourcing drug development and manufacturing.
For those in drug development and manufacturing outsourcing through the first decade and a half of this new century, it’s now safe to glance back … and finally put an end to an era focused on costs. A look back, and prognosis for what comes next, in an interview with William A. (Al) Kentrup, VP Global Quality Compliance and Systems, Takeda Pharmaceutical Company.